


Ask a doctor about a prescription for SABRILEX 500 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Sabrilex 500 mg Film-Coated Tablets
Vigabatrin
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Sabrilex is used to help control various forms of epilepsy.
It is used in addition to your current medication to treat epilepsy that is "difficult to control". Initially, it will be prescribed by a specialist. Your response to treatment will be monitored.
It is also used to control infantile spasms (West syndrome).
Do not take Sabrilex
Warnings and precautions
Talk to your doctor before starting Sabrilex if:
Visual field loss (loss of vision from the edges of your field of vision) may occur during treatment with Sabrilex. You should discuss this possibility with your doctor before starting treatment with this medicine. This visual field loss can be severe, leading to tunnel vision or loss of vision, and irreversible, so it must be detected early. It cannot be ruled out that this visual field loss may worsen after treatment is stopped. It is important that you inform your doctor immediately if you notice any change in your vision. Your doctor should perform a visual field test and a visual acuity test before you start taking Sabrilex and at regular intervals during treatment. Sabrilex may cause a decrease in vision due to eye problems such as retinal disorders, blurred vision, optic atrophy, or optic neuritis (see section 4). If your vision changes, consult an ophthalmologist. |
If you develop symptoms such as drowsiness, decreased consciousness and movement (stupor) or confusion, consult your doctor, who will decide whether to reduce the dose or stop treatment.
A small number of people being treated with antiepileptics such as vigabatrin have had thoughts of harming themselves or committing suicide. If you ever have these thoughts, contact your doctor immediately.
Children
Motor disorders have been reported in children treated for infantile spasms (West syndrome). If you observe unusual movement disorders in the child, consult your doctor, who will decide whether to consider changing treatment.
Please inform your doctor if you are taking clonazepam, as its use in combination with Sabrilex may increase the risk of sedation.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Sabrilex should not be taken in combination with other medicines that may have adverse effects on the eyes.
If you are pregnant, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine. Do not take Sabrilex during pregnancy unless your doctor tells you to. Sabrilex may cause problems for the fetus. However, do not stop treatment abruptly, as this may endanger the health of the mother and the baby.
Sabrilex passes into breast milk. If you are breastfeeding, ask your doctor before using this medicine. You should not breastfeed during treatment.
Do not drive or operate machinery if your epilepsy is not controlled.
Sabrilex can sometimes cause symptoms such as drowsiness or dizziness, and your ability to concentrate and react may be impaired. If these symptoms appear during your treatment with Sabrilex, you should not perform any hazardous tasks such as driving or operating machinery.
Visual disturbances, which can affect your ability to drive or operate machinery, have occurred in some patients taking this medicine. If you want to continue driving, you should be examined regularly (every six months) to rule out visual disturbances, even if you do not notice any changes in your vision.
Sabrilex contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; it is essentially "sodium-free".
Follow the instructions for administration of this medicine exactly as indicated by your doctor. In case of doubt, consult your doctor again.
It is important to follow your doctor's instructions exactly. Never change the dose.
The doctor prescribes the dose and adjusts it individually for patients. The recommended dose for starting treatment is 1 g (2 tablets) per day. However, your doctor may increase or decrease the dose depending on your response to treatment; the normal daily dose for adults is 2 to 3 g (4 to 6 tablets). The highest recommended dose is 3 g per day.
If you are an elderly patient and/or have kidney problems, your doctor will prescribe a lower dose.
Use in children
Resistant partial epilepsy
In children, the dose is based on age and weight. The recommended dose for starting treatment is 40 milligrams per kilogram of body weight per day. The following table indicates the number of tablets to be administered to children depending on their body weight. Remember that this is only a guide. The child's doctor will decide whether to prescribe a slightly different dose.
Weight 10-15 kg 0.5-1 g (1-2 tablets)/day
15-30 kg 1-1.5 g (2-3 tablets)/day
30-50 kg 1.5-3 g (3-6 tablets)/day
More than 50 kg 2-3 g (4-6 tablets)/day (adult dose).
Children with infantile spasms (West syndrome)
The recommended starting dose for infants with West syndrome (infantile spasms) is 50 milligrams per kilogram of body weight per day, although sometimes higher doses may be administered.
Method of administration
The route of administration is oral (by mouth).
Always swallow the tablet with at least half a glass of water.
Sabrilex can be taken before or after meals.
The daily dose can be taken as a single dose or divided into two doses.
If you take more Sabrilex than you should
If you or your child accidentally take too many Sabrilex tablets, consult your doctor immediately or go to the emergency department of the nearest hospital, accompanied by this leaflet, or call the Toxicology Information Service. Telephone 91 562 04 20, indicating the medicine and the amount taken.
Possible symptoms of overdose include drowsiness or loss/decreased level of consciousness.
If you forget to take Sabrilex
If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, take only one dose. Do not take a double dose to make up for forgotten doses.
If you stop taking Sabrilex
Do not stop taking this medicine without consulting your doctor. If your doctor decides to stop your treatment, they will give you recommendations on how to gradually reduce the dose. Do not stop it abruptly, as this may cause your seizures to return.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
As with other antiepileptic medicines, some patients may experience an increase in the number of seizures (convulsions) while taking this medicine. If this happens to you or your child, contact your doctor immediately.
Tell your doctor immediately if you experience:
Very common side effects (may affect more than 1 in 10 people)
Other side effects include:
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Very rare side effects (may affect up to 1 in 10,000 people)
Side effects of unknown frequency (frequency cannot be estimated from available data)
Other side effects in children
Very common side effects (may affect more than 1 in 10 people)
Side effects of unknown frequency (cannot be estimated from available data)
Reporting of side effects:
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Surveillance System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Do not use this medicine after the expiry date stated on the carton and blister packs. The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Place the packaging and any unused medicine in the SIGRE collection point at your pharmacy. If you have any doubts, ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Sabrilex
Core of the tablet:
Povidone K30 (E1201), Microcrystalline cellulose (E460), Sodium starch glycolate (type A), Magnesium stearate.
Coating of the tablet:
Hypromellose 15mPa.s (E464), Titanium dioxide (E171), Macrogol 8000.
Sabrilex film-coated tablets are white or almost white, oval, biconvex, with a score line on one side and Sabrilex engraved on the other side.
They are available in transparent or opaque blisters of 10 tablets.
Each pack contains 30, 50, 60, 100, or 200 tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
The Marketing Authorisation Holder is:
sanofi-aventis, S.A.
C/ Rosselló i Porcel, 21
08016 Barcelona
Spain
The manufacturer is:
Patheon France
Boulevard de Champaret
38300 Bourgoin-Jallieu (France)
Or
Sanofi-Aventis Deutschland GmbH
Industriepark Hoechst-Brueningstrase 50
65926 Frankfurt am Main (Germany)
This medicine is authorised in the Member States of the European Economic Area under the following names:
Austria:Sabril 500 mg Filmtabletten
Belgium:Sabril 500 mg filmomhulde tabletten
Denmark: Sabrilex
Finland:Sabrilex 500 mg tabletti, kalvopäällysteinen
France: Sabril 500 mg comprimé pelliculé
Germany:Sabril 500 mg Filmtabletten
Greece:Sabril 500 mg επικαλυμμ?να με λεπτ? υμ?νιο δισκ?α
Ireland:Sabril 500 mg film-coated tablets
Italy:Sabril 500 mg compresse rivestite con film
Luxembourg: Sabril 500 mg comprimés pelliculés
Netherlands:Sabril 500 mg filmomhulde tablet
Portugal: Sabril 500 mg comprimidos revestidos por pelicula
Spain:Sabrilex 500 mg comprimidos recubiertos con película
Sweden:Sabrilex 500 mg filmdragerade tabletter
United Kingdom:Sabril 500 mg film-coated tablets
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of SABRILEX 500 mg FILM-COATED TABLETS in November, 2025 is around 54.83 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for SABRILEX 500 mg FILM-COATED TABLETS – subject to medical assessment and local rules.